Cryoport(NASDAQ) CYRX

Cryoport, Inc. helps scientists ship sensitive medicines safely. It makes containers that keep items frozen during travel. These tools move life-saving treatments to patients worldwide.

Specialized Equipment and Services

• Life Sciences Services: Logistics, storage, and sample management for pharmaceutical and research firms; generated $54.9 million for the six-month period ended June 30, 2026.
• Life Sciences Products: Manufacturing of cryogenic freezers and vacuum-insulated containers for sensitive materials; generated $41.9 million for the six-month period ended June 30, 2026.
• BioLogistics Solutions: Temperature-controlled shipping using a proprietary cloud-based platform for order tracking and documentation.
• Cryoport Express Shippers: Specialized containers engineered to maintain the stability of biological commodities throughout transit.

Strategic Expansion and Partnerships

• Divested the CRYOPDP specialty courier business to DHL for $133.0 million on June 11, 2025.
• Entered a master partnership with DHL to expand service reach across Europe, the Middle East, Africa, and Asia-Pacific.
• Introduced the Fusion 800 Series, a self-sustaining cryogenic freezer that eliminates the need for a continuous liquid nitrogen supply.
• Deployed generative artificial intelligence to advance digital and information strategies for supply chain efficiency.

Global Reach and Clinical Support

Cryoport operates across the Americas, Europe, the Middle East, Africa, and Asia-Pacific regions. The company supports the clinical development of therapies by managing logistics for 779 clinical trials as of June 30, 2026.

Performance by the Numbers

• Total revenue was $96.8 million for the six-month period ended June 30, 2026, up 11.9% year over year.
• Life Sciences Services revenue reached $54.9 million for the six-month period ended June 30, 2026, up 16.2% year over year.
• Commercial cell and gene therapy revenue rose to $18.0 million for the six-month period ended June 30, 2026, up 23.2% year over year.
• Cash and cash equivalents totaled $269.3 million as of June 30, 2026.

Bottom Line

Cryoport has transitioned into a specialized provider focused on high-value cell and gene therapy markets. Its divestiture of courier assets and strategic partnership with DHL highlight a focus on technology-driven infrastructure.